Vogt Frederick G 4

What Happened
Frederick G. Vogt, Interim CEO & General Counsel and a director of Iovance Biotherapeutics (IOVA), had 41,668 restricted stock units (RSUs) vest on June 1, 2026 and converted those RSUs into common stock (no exercise price). To satisfy mandatory tax withholding, 17,701 of the vested shares were withheld (reported as a disposition) at $3.96 per share, totaling $70,096. The net shares delivered to Vogt equal 41,668 − 17,701 = 23,967 (using the reported $3.96/share implies roughly $95k value for the net shares).

Key Details

• Transaction date: 2026-06-01; Form filed: 2026-06-03 (timely).
• Primary codes: M = conversion/exercise of derivative (RSU → shares); F = shares withheld to cover tax liability (not an open-market sale).
• Shares vested/converted: 41,668 RSUs → 41,668 shares.
• Shares withheld for taxes: 17,701 @ $3.96 = $70,096 (withheld by issuer).
• Net shares delivered to insider after withholding: 23,967.
• Footnotes: each RSU equals one share; remaining RSUs from the March 1, 2024 grant will vest in equal quarterly installments; withholding was mandatory and not an open-market sale.

Context
This was an award vesting and tax-withholding event (routine compensation processing), not a buy or open-market sale that signals trading sentiment. For retail investors: RSU vesting increases insider ownership when shares are delivered, but the withheld shares simply satisfy tax obligations and do not represent a market sale.